Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and Immunogenicity Study of GRAd-COV2 Vaccine in Healthy Adults
NCT04528641Phase 1Completed
- Sponsor
- ReiThera
- Start
- Aug 2020
- Primary completion
- May 2021
- Modality
- Prophylactic Vaccines, Adenoviral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of GRAd-COV2 in coronavirus disease 2019 (COVID-19), sponsored by ReiThera. Primary endpoints: Occurrence of Solicited Local AE Signs and Symptoms at 7 days, Occurrence of Solicited Systemic AE Signs and Symptoms at 7 days and 3 more. Started Aug 2020; status: completed.
02
Drugs
GRAd-COV2
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04528641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04528641.